FDA approves Moderna mRNA flu for 50+

Moderna said on August 5 that the U.S. Food and Drug Administration approved mFLUSIVA, its mRNA-based influenza vaccine, for adults 50 and older in the United States. The authorization gives Moderna its first approved flu shot and extends the company’s commercial mRNA franchise beyond COVID-19 and RSV, according to the company’s recent investor materials. FDA briefing documents published ahead of a June 18 advisory committee meeting identified mFLUSIVA, also called mRNA-1010, as Moderna’s proposed influenza vaccine for people 50 and older. Moderna said the shot will be available in the United States this fall. ### What exactly did the FDA clear? FDA materials for the June 18 Vaccines and Related Biological Products Advisory Committee meeting described the application as a biologics license request for “MFLUSIVA (Influenza Vaccine, mRNA)” for the prevention of influenza disease in people 50 years of age and older. The same FDA materials identified Moderna TX, Inc. as the applicant and listed the proposed trade name as mFLUSIVA. (fda.gov) The FDA’s public list of licensed vaccines already includes multiple influenza vaccines, but the Moderna product is notable because it uses messenger RNA technology, the platform better known from COVID-19 vaccines. FDA’s vaccine licensing page shows approved mRNA COVID-19 products and multiple flu vaccines made with other approaches. ### Why does the age cutoff matter? (fda.gov) The 50-and-older label puts Moderna’s shot into a market that includes adults who face rising flu risk with age, while stopping short of a universal adult indication. FDA’s June 18 meeting notice said the review covered persons 50 years of age and older. (fda.gov) CDC guidance for the 2026-27 flu season says everyone 6 months and older should receive an age-appropriate influenza vaccine. CDC also says adults 65 and older should preferentially receive a higher-dose, adjuvanted, or recombinant flu vaccine rather than a standard-dose unadjuvanted shot when one of those options is available. That means mFLUSIVA enters a market where recommendations already vary by age group. (fda.gov) ### What do we know about the regulatory path? June 18 was the date FDA’s vaccine advisers met to discuss the safety and effectiveness of mFLUSIVA. Moderna told investors on July 31 that August 5 was the Prescription Drug User Fee Act goal date for the product, signaling that a decision was imminent. (cdc.gov) The FDA briefing package released for that June meeting said the advisory committee review was intended to gather outside input before the agency made a final determination. Trade coverage of the meeting reported that the panel voted 9-0 in favor of the vaccine’s benefit-risk profile for adults 50 through 64 and those 65 and older. ### Is this Moderna’s first non-COVID respiratory expansion? Moderna’s recent product lineup already includes approved COVID-19 and RSV vaccines, according to company and FDA materials. (fda.gov) The company’s July 31 quarterly update said mFLUSIVA could become Moderna’s fifth approved product, and Moderna’s consumer and professional sites list approved mRNA COVID-19 vaccines as well as mRESVIA for RSV. (fda.gov) The broader flu program is still moving through other regulators. Moderna said in its July 31 quarterly update that regulatory filings for mRNA-1010 were under review in Europe, Canada and Australia, with potential approvals expected to begin in 2026. ### What happens before patients can get it? March 13, 2026 was the date FDA published its recommended influenza virus strains for the 2026-27 U.S. season. (investors.modernatx.com) CDC says 2026-27 flu vaccines are available for use in people 6 months and older during the season, and Moderna said its newly approved shot will be distributed this fall. This fall will be the next concrete milestone. (finviz.com) Providers and pharmacies will be making decisions in a market where CDC still gives special preference to certain flu shots for adults 65 and older, while Moderna begins the U.S. rollout of mFLUSIVA for people 50 and older. (cdc.gov) (fda.gov)